Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine (MindMed) Inc.

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Mind Medicine, with a price target of $55.00. Trucchio...

H.C. Wainwright Sticks to Its Buy Rating for Mind Medicine (MNMD)

Mind Medicine ( ($MNMD) ) has shared an update. Mind Medicine (MindMed) Inc. announced the successful closing of its public offering, raising appro...

MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations

The latest update is out from Mind Medicine ( ($MNMD) ). MindMed announced the issuance of inducement grants to three newly hired non-executive emp...

MindMed Issues Inducement Grants to New Employees

The latest announcement is out from Mind Medicine ( ($MNMD) ). On October 29, 2025, MindMed entered into an underwriting agreement for a public off...

Mind Medicine Completes Successful Public Offering

Oppenheimer analyst Jay Olson maintained a Buy rating on Mind Medicine today and set a price target of $25.00. The company’s shares closed yesterda...

Mind Medicine (MNMD) Receives a Buy from Oppenheimer

Mind Medicine Inc. (($MNMD)) announced an update on their ongoing clinical study. Study Overview: Mind Medicine Inc. is conducting a Phase 3 trial ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MNMD	$10.68	-1.84%	1.73M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MNMD	$10.68	-1.8%	1.73M
3
4
5
6

MNMD

MNMD

Get Mind Medicine (MindMed) Inc. Data in Excel

Get Mind Medicine (MindMed) Inc. Data in Excel